Hemophilia Accelerated Approval: Factor Activity Useful Surrogate, Panel Says
Variability in assays is important issue in managing patients at “trough” levels, experts at US FDA hemophilia workshop suggest. However, assuming some significant level of activity is restored, the exact level isn’t overly important.
You may also be interested in...
Although clotting factor activity levels may someday be validated as a surrogate endpoint, the currently recommended primary efficacy measure for traditional approval remains annualized bleeding rate, agency says in final guidance.
Development guidance from CBER recommends comparing investigational gene therapy products to existing prophylaxis treatment.
National Academies report argues that technologies cannot only be evaluated in the context of specific products, and FDA guidance should become both ‘more fluid and targeted.’